ArticleBMC health services research2026
Perceived barriers and opportunities to the continuous distribution of ivermectin in the Cameroon primary health care system: an exploratory study of major stakeholders.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOnchocerciasis, a debilitating parasitic disease transmitted by blackflies, remains a significant public health concern in Cameroon. While mass drug administration (MDA) campaigns with ivermectin offer success in controlling transmission, logistical and financial challenges threaten long-term sustainability. Integrating ivermectin distribution into the existing primary healthcare system (PHC) could offer a promising alternative. We aimed to explore challenges and opportunities associated with this integration.
methodsThis study employed a mixed-methods approach conducted across five regions in Cameroon. Qualitative methods (in-depth interviews and focus group discussions) were used to explore stakeholder perceptions at all levels of the distribution ladder. Quantitative data on program costs and drug coverage were extracted from district campaign reports.
resultsStakeholder perspectives on Ivermectin Integration (n = 130) revealed strong support for partial integration within the primary healthcare system. Stakeholders from various levels (health system, healthcare workers, and community members) perceived this approach as simple and readily implementable. Most stakeholders viewed this approach as viable to ensure a continued ivermectin administration despite funding shortfalls. However, concerns were raised regarding management of adverse events and a potential misuse of ivermectin. Additionally, our analysis revealed an estimated cost of 53 CFA francs (0.1 USD) per person treated.
conclusionBy exploring the partial integration of ivermectin distribution within Cameroon's primary healthcare system, this research paves the way for sustainable onchocerciasis control. Clinical trials and community education initiatives are crucial next steps to validate and optimize this promising strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.